Patents by Inventor Simon Shaw

Simon Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10947216
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: March 16, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • Publication number: 20210069208
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP 1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Inventors: Jiaxin Yu, Ihab Darwish, Vanessa Taylor, Rao Kolluri, Yan Chen, Simon Shaw, Somasekhar Bhamidipati, Zhushou Luo
  • Publication number: 20210070744
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor
  • Publication number: 20210070743
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
  • Patent number: 10941134
    Abstract: Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by “B”, T, R3, R4, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 9, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Donald Payan, Rajinder Singh, Simon Shaw, David Carroll, Yasumichi Hitoshi
  • Publication number: 20210061798
    Abstract: Disclosed herein are embodiments of a pyrazole compound according to formula I. Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer and/or the composition may be a spray-dried formulation. Also disclosed is a method for using the compound and/or composition. The compound and/or composition may be useful to inhibit an IRAK protein and/or to ameliorate, treat and/or prevent an IRAK-associated disease or condition in a subject.
    Type: Application
    Filed: August 28, 2020
    Publication date: March 4, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Lu Chou, Matt Duan, Ihab Darwish, Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor, Yan Chen, Dazhong Fan, Zhushou Luo
  • Publication number: 20210047217
    Abstract: An electrochlorination system includes an electrolyzer fluidically connectable between a source of feed fluid and a product fluid outlet, and a sub-system configured to one of increase a pH of the feed fluid, or increase a ratio of monovalent to divalent ions in the feed fluid, upstream of the electrolyzer.
    Type: Application
    Filed: February 27, 2019
    Publication date: February 18, 2021
    Applicant: Evoqua Water Technolgies LLC
    Inventors: Joshua Griffis, Simon P. Dukes, LI-Shiang Liang, Darren Dale, Michael Shaw, Paul Beddoes, George Y. Gu
  • Publication number: 20210040053
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: October 16, 2020
    Publication date: February 11, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Publication number: 20210009537
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 16, 2020
    Publication date: January 14, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Publication number: 20210002237
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 16, 2020
    Publication date: January 7, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Publication number: 20210002236
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 16, 2020
    Publication date: January 7, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Publication number: 20200407332
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 16, 2020
    Publication date: December 31, 2020
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Patent number: 10841162
    Abstract: A method is provided for replacing an enterprise legacy PBX with an advanced IP-enabled system, comprising: (i) providing configuration data of the legacy PBX; (ii) analyzing the data provided, and detecting missing details from among the legacy PBX configuration data; and detecting conflicts that exist among the legacy PBX configuration data; (iii) retrieving information associated with missing details by approaching data source(s) other than the source for the legacy PBX configuration data, and resolving detected conflicts; (iv) converting data associated with the users of the legacy PBX for use by a system implementing an advanced IP-enabled solution; and (v) configuring the advanced IP-enabled system accordingly.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: November 17, 2020
    Assignee: UNIVONIX LTD.
    Inventors: Benjamin Abraham Ben Ami, Simon Shaw
  • Patent number: 10815206
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: October 27, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Publication number: 20200129926
    Abstract: An electrochemical separation device includes a first electrode, a second electrode, and a cell stack including a plurality of sub-blocks each having alternating depleting compartments and concentrating compartments and each including frame and channel portions disposed between the first electrode and the second electrode. An internal seal formed of a first material is disposed between and in contact with the channel portions between adjacent sub-blocks in the cell stack and configured to prevent leakage between depleting compartments and concentrating compartments in the adjacent sub-blocks. An external seal formed of a second material having at least one material parameter different from the first material is disposed between and in contact with the frames of the adjacent sub-blocks in the cell stack and configured to prevent leakage from an internal volume of the electrochemical separation device to outside of the electrochemical separation device.
    Type: Application
    Filed: July 11, 2018
    Publication date: April 30, 2020
    Applicant: Evoqua Water Technologies LLC
    Inventors: Michael J. Muse, Joshua Griffis, LI-Shiang Liang, Michael Shaw, Simon P. Dukes
  • Publication number: 20200017465
    Abstract: Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by “B”, T, R3, R4, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.
    Type: Application
    Filed: June 25, 2019
    Publication date: January 16, 2020
    Inventors: Dane Goff, Donald Payan, Rajinder Singh, Simon Shaw, David Carroll, Yasumichi Hitoshi
  • Publication number: 20190359593
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: August 2, 2019
    Publication date: November 28, 2019
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • Publication number: 20190337907
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: May 2, 2019
    Publication date: November 7, 2019
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor
  • Patent number: 10414753
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: September 17, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • Publication number: 20190263697
    Abstract: A water treatment system for producing potable water and water for irrigation from saline water, the system includes an electrodialysis apparatus including one or more monovalent selective membranes and having an inlet fluidly connectable to a source of water to be treated, a diluate outlet, and a concentrate outlet, a nanofiltration apparatus positioned downstream of the electrodialysis apparatus and having an inlet fluidly connectable to the diluate outlet of the electrodialysis apparatus, a permeate outlet, and a retentate outlet, and an electrolyzer in fluid communication with one of the concentrate outlet and the retentate outlet, and configured to generate a product stream including one or more of chlorine gas, hypochlorite ion, sodium hydroxide, sulfuric acid, hydrochloric acid, or sodium hypochlorite.
    Type: Application
    Filed: February 27, 2019
    Publication date: August 29, 2019
    Applicant: Evoqua Water Technologies LLC
    Inventors: Gary C. Ganzi, Joahua Griffis, Simon Dukes, Li-Shiang Liang, Darren Adrian Dale, Michael Shaw, Paul Beddoes, George Gu